Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00085553 · ClinicalTrials.gov registry record · Phase 1
Tipifarnib and Erlotinib Hydrochloride in Treating Patients With Advanced Solid Tumors
A Phase 1 study of Solid Neoplasm, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 29
- Enrollment target
- 1
- Study location
NCT00085553: Completed Phase 1 study of Solid Neoplasm, sponsored by National Cancer Institute (NCI).
NCT00085553 is a Phase 1 study of Solid Neoplasm that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 29 participants, below the 941-participant average among 12 other Solid Neoplasm trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00085553, a Phase 1 study of Solid Neoplasm, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 29 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase I trial studies the side effects and best dose of tipifarnib and erlotinib hydrochloride in treating patients with solid tumors that have spread to other places in the body. Tipifarnib and erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Primary Outcome
The number and severity of all adverse events (overall, by dose-level, and by tumor group) will be tabulated and summarized in this patient population. The grade 3+ adverse events will also be described and summarized in a similar fashion.
Conditions Studied
Interventions
- OTHER Laboratory Biomarker Analysis
- DRUG Tipifarnib
- DRUG Erlotinib Hydrochloride
- OTHER Pharmacological Study
Study Locations (1)
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2004-05-20 |
| Est. Completion | 2018-05-16 |
| Phase | Phase 1 |
What the finished NCT00085553 record still lists
NCT00085553 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 29 participants, a relatively small participant target, below the 941-participant average among 12 other Solid Neoplasm trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Solid Neoplasm appearing as the primary indexed condition, and to 4 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT00085553 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT00085553 about?
NCT00085553 is a clinical study titled "Tipifarnib and Erlotinib Hydrochloride in Treating Patients With Advanced Solid Tumors". This phase I trial studies the side effects and best dose of tipifarnib and erlotinib hydrochloride in treating patients with solid tumors that have spread to other places in the body. Tipifarnib and erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed fo...
What is the current status of trial NCT00085553?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 29 participants. The study started on 2004-05-20. Estimated completion is 2018-05-16.
What conditions does trial NCT00085553 study?
This clinical trial studies the following conditions: Solid Neoplasm.
What interventions are being tested in trial NCT00085553?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Tipifarnib (DRUG), Erlotinib Hydrochloride (DRUG), Pharmacological Study (OTHER).
Who is sponsoring clinical trial NCT00085553?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00085553 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00085553's enrollment target sits among peer trials
29 11th of 12 higher than 1 of 12 other Solid Neoplasm trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Solid Neoplasm trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CTF
RECRUITING · Phase 1
-
Veliparib, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Non-Hodgkin Lymphoma
ACTIVE NOT RECRUITING · Phase 1
-
Pazopanib Hydrochloride in Treating Patients With Advanced or Refractory Solid Tumors
ACTIVE NOT RECRUITING · Phase 1
-
Trebananib in Treating Younger Patients With Relapsed or Refractory Solid Tumors, Including Central Nervous System Tumors
COMPLETED · Phase 1
-
Selumetinib and Cyclosporine in Treating Patients With Advanced Solid Tumors or Advanced or Metastatic Colorectal Cancer
COMPLETED · Phase 1
-
Ilorasertib in Treating Patients With CDKN2A-deficient Advanced or Metastatic Solid Cancers That Cannot Be Removed by Surgery
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02429557 · 29 participants · Phase 1
Hemodynamic Mechanisms of Abdominal Compression in the Treatment of Orthostatic Hypotension in Autonomic Failure
- NCT02568878 · 29 participants · Phase 3
Creatine for Depressed Male and Female Methamphetamine Users
- NCT03014401 · 29 participants · NA
The Effect of Adipose-Derived Stem Cells for Knee Osteoarthritis
- NCT03128996 · 29 participants · Phase 1
Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI